Literature DB >> 10677519

Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen.

R Weissert1, A Lobell, K L de Graaf, S Y Eltayeb, R Andersson, T Olsson, H Wigzell.   

Abstract

DNA vaccines that encode encephalitogenic sequences in tandem can protect from subsequent experimental autoimmune encephalomyelitis induced with the corresponding peptide. The mechanism for this protection and, in particular, if it is specific for the amino acid sequence encoding the vaccine are not known. We show here that a single amino acid exchange in position 79 from serine (nonself) to threonine (self) in myelin basic protein peptide MBP68-85, which is a major encephalitogenic determinant for Lewis rats, dramatically alters the protection. Moreover, vaccines encoding the encephalitogenic sequence MBP68-85 do not protect against the second encephalitogenic sequence MBP89-101 in Lewis rats and vice versa. Thus, protective immunity conferred by DNA vaccination exquisitely discriminates between peptide target autoantigens. No bystander suppression was observed. The exact underlying mechanisms remain elusive because no simple correlation between impact on ex vivo responses and protection against disease were noted.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10677519      PMCID: PMC26497          DOI: 10.1073/pnas.030390097

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

Review 1.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

2.  Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein.

Authors:  S Brocke; K Gijbels; M Allegretta; I Ferber; C Piercy; T Blankenstein; R Martin; U Utz; N Karin; D Mitchell; T Veromaa; A Waisman; A Gaur; P Conlon; N Ling; P J Fairchild; D C Wraith; A O'Garra; C G Fathman; L Steinman
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

3.  Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis.

Authors:  A Lobell; R Weissert; S Eltayeb; C Svanholm; T Olsson; H Wigzell
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

4.  Donor-specific blood transfusion-induced tolerance in adult rats with a dominant TCR-Vbeta rearrangement in heart allografts.

Authors:  P Douillard; C Pannetier; R Josien; S Menoret; P Kourilsky; J P Soulillou; M C Cuturi
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

5.  Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity.

Authors:  A Waisman; P J Ruiz; D L Hirschberg; A Gelman; J R Oksenberg; S Brocke; F Mor; I R Cohen; L Steinman
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis.

Authors:  N H Javed; I E Gienapp; K L Cox; C C Whitacre
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

7.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen.

Authors:  P V Lehmann; T Forsthuber; A Miller; E E Sercarz
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

8.  Peripheral deletion of antigen-reactive T cells in oral tolerance.

Authors:  Y Chen; J Inobe; R Marks; P Gonnella; V K Kuchroo; H L Weiner
Journal:  Nature       Date:  1995-07-13       Impact factor: 49.962

9.  Protective influences on experimental autoimmune encephalomyelitis by MHC class I and class II alleles.

Authors:  M Mustafa; C Vingsbo; T Olsson; S Issazadeh; A Ljungdahl; R Holmdahl
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

10.  Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein.

Authors:  K W Wucherpfennig; J L Strominger
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

View more
  10 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

2.  Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes.

Authors:  J S Petersen; S Bregenholt; V Apostolopolous; D Homann; T Wolfe; A Hughes; K De Jongh; M Wang; T Dyrberg; M G Von Herrath
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 3.  Insights into the immunopathogenesis of multiple sclerosis.

Authors:  Niels Hellings; Jef Raus; Piet Stinissen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 4.  Targeting dendritic cells to treat multiple sclerosis.

Authors:  Manuel Comabella; Xavier Montalban; Christian Münz; Jan D Lünemann
Journal:  Nat Rev Neurol       Date:  2010-08-17       Impact factor: 42.937

5.  Altered peptide ligands of myelin basic protein ( MBP87-99 ) conjugated to reduced mannan modulate immune responses in mice.

Authors:  Maria Katsara; Elizabeth Yuriev; Paul A Ramsland; Theodore Tselios; George Deraos; Athanasios Lourbopoulos; Nikolaos Grigoriadis; John Matsoukas; Vasso Apostolopoulos
Journal:  Immunology       Date:  2009-12       Impact factor: 7.397

6.  Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease.

Authors:  Zhongmei Chen; Yunpeng Yang; Xu Yang; Changqing Zhou; Fengqun Li; Peng Lei; Ling Zhong; Xin Jin; Guoguang Peng
Journal:  Neurol Sci       Date:  2013-01-25       Impact factor: 3.307

Review 7.  Emerging immunopharmacological targets in multiple sclerosis.

Authors:  Mojtaba Farjam; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  J Neurol Sci       Date:  2015-09-14       Impact factor: 3.181

8.  Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis.

Authors:  Nicolás Fissolo; Carme Costa; Ramil N Nurtdinov; Marta F Bustamante; Victor Llombart; María J Mansilla; Carmen Espejo; Xavier Montalban; Manuel Comabella
Journal:  J Neuroinflammation       Date:  2012-06-22       Impact factor: 8.322

9.  Impaired autoimmune T helper 17 cell responses following DNA vaccination against rat experimental autoimmune encephalomyelitis.

Authors:  Asa Andersson; Magnus Isaksson; Judit Wefer; Anna Norling; Amilcar Flores-Morales; Fredrik Rorsman; Olle Kämpe; Robert A Harris; Anna Lobell
Journal:  PLoS One       Date:  2008-11-10       Impact factor: 3.240

10.  Tolerogenic β2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome.

Authors:  Ya-Hsuan Chao; Der-Yuan Chen; Joung-Liang Lan; Kuo-Tung Tang; Chi-Chien Lin
Journal:  PLoS One       Date:  2018-06-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.